The F2R Receptor pipeline drugs market research report outlays comprehensive information on the F2R Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the F2R Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Respiratory, Cardiovascular, Central Nervous System, and Gastrointestinal which include the indications Asthma, Unspecified Respiratory Disorders, Thrombosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Migraine, Unspecified Neurologic Disorders, Inflammatory Bowel Disease, and Metabolic Dysfunction-Associated Steatohepatitis (MASH). It also reviews key players involved in F2R Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The F2R Receptor pipeline targets constitutes close to 28 molecules. Out of which, approximately 23 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 7, and 11 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 1 molecule.
F2R Receptor overview
F2R receptor (F2R) is a high affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. It may play a role in platelet activation and in vascular development.
For a complete picture of F2R Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.